Breast Cancer First-line Treatment with CDK4/6 Inhibitor
We are pleased to present an insightful case study on managing the adverse effects associated with breast cancer treatment. This case study is presented by our esteemed Key Opinion Leader (KOL), Dr. Wendy Chan, a renowned expert in oncology and patient care. Dr. Chan will delve into the details of a patient’s journey, focusing on practical strategies to manage treatment-related side effects while maintaining the patient’s quality of life.
Breast Cancer First-line Treatment with CDK4/6 Inhibitor Read More »

